Get to know our clinical trials

Trial of mosunetuzumab or glofitamab in combination with cc-220 and cc-99282 in patients with b-lymphocyte non-Hodgkin's lymphoma

THE PURPOSE OF THIS STUDY IS TO ANALYZE THE SAFETY AND EFFICACY OF MOSUNETUZUMAB IN COMBINATION WITH CC-220 OR CC-99282 (GROUP 1), OR GLOFITAMAB AND OBINUTUZUMAB IN COMBINATION WITH CC-220 OR CC-99282 (GROUP 2) AT DIFFERENT DOSE LEVELS AND DOSING SCHEDULES TO FIND OUT WHAT EFFECTS THIS DRUG COMBINATION HAS, EITHER GOOD OR BAD, ON YOU AND YOUR CANCER.

Status
In recruitment
headquarters
Madrid

Technical Summary

  • PHASE IB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF MOSUNETUZUMAB OR GLOFITAMAB IN COMBINATION WITH CC-220 AND CC-99282 IN PATIENTS WITH B-LYMPHOCYTE NON-HODGKIN'S LYMPHOMA
  • Code EudraCT: 2021-005745-33
  • Protocol number: CO43805
  • Promoter: Roche Farma, S.A.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.